Member Info for PhilBanks

Great presentation and confirmation of what sajy has said about the intention of directors to buy once out of closed period.

Ross is a breath of fresh air. Need to watch the presentation again, plenty to unpack. The focus is on generating shareholder value and the strategy is now clear, coherent and absolutely achievable.

One comment stood out which I shall attempt to paraphrase, 'we're going to generate dosh and it won't be through dilution'.

Yes Clive, I think you make an important point. Its a considerable investment from fosun (in relation to developing a manufacturing plant within the next 12 months) and really validates where they see CTX going in the future.

The headline figures for Rene aren't exciting at this stage, but the story developing is very interesting.

It's just a shame it's taken so long to get to this stage, as the fosun deal did appear to stagnate for a period. The fact it is absolutely still moving forward is fantastic to see.

Good to see the additional terms finalised at last this morning. The figures don't exactly blow the doors off, but do represent a shift towards finally monitizing the IP, as the business begins it's evolution into a proper commercial entity.

Hopefully further deals can follow and we can secure regular income that underpins the value of the business. The results and analyst presentation should provide more colour next week.

Paid client access

The full write up (71 pages) is excellent, very detailed and comprehensive. It's a shame the share price in no way reflects what Liberum have observed. Hopefully time will tell.

The company had been run like a well funded university experiment that had got out of hand. There's proper business people running it now and I expect them to finally deliver on the promise of shareholder returns. From these levels the upside could be remarkable. That said, it's a disgrace that it was ever allowed to reach these levels in the first place.

Well, they announced it via RNS saying negotiations relating to further terms are ongoing...

'Additional agreement with Fosun Pharma for CTX

Progression with Fosun Pharma underscores commitment to CTX stroke disability programme



ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem cell and Exosome Technologies, announces that following on from the original Fosun Pharma ("Fosun") licensing agreement announced on 9 April 2019, the Company has signed an additional agreement with Fosun, on 5 January 2022, setting out the first steps in the potential technology transfer of the CTX drug product for the stroke disability programme.



The agreement allows for £320,000 to be invoiced on signing with further payments expected, based on services and CTX cell bank vials to be supplied by ReNeuron in the future, although these are contingent on signing a supplemental payment terms agreement which is currently under discussion.



ReNeuron will update the market further once agreement on these terms have been reached.



Olav Hellebø, Chief Executive Officer, commented: "We are pleased to announce progress in the technology transfer of the CTX drug product to Fosun and believe this highlights the commitment Fosun has to the programme in Greater China."'

Due update on fosun terms, so that's the next thing on the horizon. Its taken a long time to negotiate though, so perhaps we may see something more left field announced? Perhaps Fosun are seeking a further deal for exosomes as well? Safe to say we are due some good news and positive momentum for a change.

The technicals appear to be shifting at long last, perhaps we have seen the bottom? Need some good updates now to pique the interest and build sentiment.

Difficult to say if it's turned a corner. The decline has been frankly shocking.

If/when any director buys come it will be interesting - hopefully not just token gestures. The caliber of the ceo replacement should also be telling.

I'm still in for a lot of shares here, but my enthusiasm has certainly been dented and the board need to provide confidence that the exosomes platform is going to transform the company, because we are firmly staring at last chance saloon otherwise.

Thanks for the observations Clive/sajy. I'm conflicted about whether I should buy more. Part of me thinks 'how can it possibly get any lower than it is now?'. The other part of me is thinking 'it could get much lower, along with all other stocks, depending on how things escalate with Russia/Ukraine'.

Think I'm just going to hold for now. Nursing heavy losses already, and don't have high expectations for a positive resolution in Ukraine unfortunately.

Just been having a look and he actually was in SNG as well, sold out April 2020 for a tidy profit. Although it would be worth significantly more if he'd held them.

Hopefully he can have similar success with Rene.

Griffiths is/was heavy in silence therapeutics (sln), which he's done extremely well with. Synairgen (sng) has also multibagged in that time, but Griffiths hasn't been involved there, as far as I'm aware.

Either way, Griffiths going big here and Ross being chairman (and basically now taking the reigns after Olav 'resigning') is a tried and tested formula. Doesn't mean success is guaranteed, but the signs are very good, despite the still lowly share price.

Get the feeling Griffiths will end up with over 20% stake and we'll see Ross taking a fair chunk also. Hope so.

From the Ian Ross reign at Redx...

"Redx Pharma PLC (LON:REDX) may turn out to be a turnaround story that will be studied in finance textbooks in the future."

https://www.proactiveinvestors.co.uk/companies/news/926712/redx-pharma-the-three-year-journey-from-administration-to-ftse-100-deal-926712.html

It's been clear for a while that the power has shifted within Rene, and I think the announcement today demonstrates this.

Hopefully Ross can replicate the success he achieved in very similar circumstances at Redx a few years ago and appoint a heavy hitter when the time is right...

https://www.proactiveinvestors.co.uk/companies/news/195633/redx-pharma-shares-soar-48-after-it-recruits-heavy-hitter-from-drugs-major-astrazeneca-195633.html

Frankly, given how the hRPC trial has developed under his stewardship, I'm not sure how greatly he'll be missed.

As BoH points out, the new direction the company is going in perhaps isn't suited to his skillset in any case.

'bastardman', dunno why that made me laugh so much, but it did. Keep up the good work, dunk1973.

hopeful; I agree with your understanding, but happy to be corrected if someone else knows better in that regard.

Think you might be asking the wrong group of people! If any of us were good at predicting where the share price would be in 6 months time, then safe to say we would have sold out a while ago.

But in an attempt to answer your question, the company is currently valued at only around £4 to 5m above its cash reserves, so you would hope/expect that the share price shouldn't drop any more.

The potential for exosomes is huge, but it's difficult to say what will be announced on that front over the next 6 months. Fosun developments could be interesting, but no guarantees.

Investment case surely looks weighted to the upside from these levels. If you're new to the share then a good starting point would be the investor presentation from Friday. Link below...

https://youtu.be/dR_bbiZr_Y4

Looking a bit short of obvious near term catalysts now.

We should expect further collaboration announcements by the sounds of it, which is positive, but obviously the market doesn't value that too highly right now (given we already have 7 ongoing and the share price is on the floor).

Further fosun movement and terms of additional technology transfer are likely to be forthcoming soon. I have no idea how lucrative this would be, but at least it will demonstrate progress and commitment from fosun.

Additional POC exosomes data from one of the global/large pharma collaborations could perhaps be expected in the next 6 months, and this would then presumably lead to licencing negotiations.

Sounds like an equity raise is firmly off the table for now at these levels, but if no licencing deal or fosun milestone payment is secured in the next 12 months then it spells trouble.

All-in-all the investor presentation was interesting to see, and hopefully puts a stop to the share price decline, but doesn't outline an immediate bull case for us to get excited about.

Hopefully something left-field gets announced, but seems like it needs to go in the bottom drawer for the time being. If you're buying at these levels then the upside could be really significant based on any licencing deal terms. Paper losses could well reduce the appetite for further risk here though.